Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercus rubra pollen extract is a biological allergenic extract derived from the pollen of the Northern Red Oak tree. It is primarily utilized in the diagnosis and treatment of immediate hypersensitivity (Type I) allergic reactions. As a diagnostic tool, it is used in skin testing (percutaneous or intradermal) to identify patients with IgE-mediated sensitivity to red oak allergens. Therapeutically, it is employed in allergen immunotherapy (subcutaneous injection) to desensitize patients by inducing immunological tolerance. The extract contains various proteins and glycoproteins that act as allergens, triggering the immune system to produce specific IgE antibodies in sensitized individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercus rubra pollen.